Deep brain stimulation (DBS) helps Parkinson’s disease by delivering continuous electrical pulses to specific brain structures, interrupting the abnormal nerve signals that cause tremor, stiffness, and slow movement. In one study, motor scores improved 53% after two years with DBS, compared to just 4% improvement with medication alone. The treatment doesn’t cure Parkinson’s or stop its progression, but it can dramatically expand the portion of each day spent free of motor symptoms.
What Happens Inside the Brain
In Parkinson’s disease, the loss of dopamine-producing cells throws off communication in a network of deep brain structures called the basal ganglia. Without enough dopamine, these structures get stuck in abnormal rhythmic firing patterns that interfere with normal movement commands traveling to the motor cortex. The result is the hallmark symptoms: tremor at rest, rigid muscles, and movements that feel slow and effortful.
DBS works by placing thin electrodes into this circuit and sending rapid electrical pulses, typically 130 times per second, from a battery-powered device implanted in the chest. Scientists once thought this simply shut down the targeted area, mimicking the effect of surgically destroying it. The picture now looks more complex. The electrical current primarily activates the insulated fibers (axons) passing through the target region, which alters neurotransmitter release and disrupts the pathological oscillations rippling between the basal ganglia and the motor cortex. In practical terms, DBS overrides the “noisy” signals that lock up movement, restoring something closer to normal communication in the motor circuit.
Where the Electrodes Go
Surgeons typically target one of two small structures deep in the brain: the subthalamic nucleus (STN) or the globus pallidus internus (GPi). Both targets improve motor symptoms, but they differ in meaningful ways.
A three-year follow-up study published in Neurology found that STN stimulation produced significantly greater motor improvement and allowed a much larger reduction in medication. Patients with STN targets cut their daily medication roughly in half, while GPi patients stayed on nearly twice as much. The STN group also showed a trend toward better overall physical functioning when assessed off medication. In that same study, eight patients who didn’t respond well to GPi stimulation were switched to STN, while only one STN patient needed a GPi revision, suggesting STN may be the more reliable target for many people.
GPi stimulation still has a role. Some clinicians prefer it for patients who have cognitive concerns, since STN stimulation carries a slightly higher risk of affecting verbal fluency. The choice between targets is individualized based on your symptom profile and overall health.
Which Symptoms Improve
DBS is most effective for the motor symptoms that also respond to levodopa: tremor, rigidity, and bradykinesia (slowness of movement). The gains can be substantial. Research from Oregon Health & Science University found that after STN surgery, the percentage of waking hours spent without troublesome motor symptoms jumped from 27% to 74%. For GPi surgery, that figure rose from 28% to 64%. For many patients, this means going from spending most of the day struggling with symptoms to spending most of the day moving comfortably.
DBS also helps smooth out the “on-off” fluctuations that develop after years of levodopa use, those unpredictable swings between periods of good movement and periods where medication wears off or triggers involuntary writhing movements called dyskinesias. By providing constant stimulation, DBS reduces dependence on the peaks and valleys of medication timing. Sleep quality tends to improve as well, with longer total sleep duration and more time in deep sleep stages.
Symptoms That Don’t Respond Well
DBS has clear limits. Cognitive function, measured by standard screening tests, generally does not change after surgery, and some studies show a decline in verbal fluency after STN stimulation specifically. Balance and gait freezing, two of the most disabling late-stage symptoms, respond inconsistently. Speech problems often don’t improve and can occasionally worsen. Sleep-related issues like periodic limb movements and sleep apnea are unaffected. Social support and quality-of-life domains tied to cognition may not see lasting benefit either. A useful rule of thumb: if a symptom doesn’t improve when you take levodopa, it’s unlikely to improve with DBS.
How Medication Changes After Surgery
One of the major practical benefits of DBS is reducing the medication burden. In a study tracking patients over three years, the average daily levodopa equivalent dose dropped from about 1,250 mg before surgery to roughly 640 mg one month after. That reduction partially eroded over time, rising to about 860 mg by the three-year mark, reflecting the progressive nature of Parkinson’s. Still, at three years, 27% of patients were taking less than half their pre-surgery dose. Fewer pills means fewer side effects, less time managing complicated dosing schedules, and often less dyskinesia.
The Surgery and Recovery Timeline
DBS implantation typically happens in stages. The electrode placement in the brain is often done with the patient awake so the surgical team can test responses in real time, though some centers now use imaging-guided techniques under general anesthesia. A second procedure places the pulse generator (the battery pack) under the skin near the collarbone. Swelling around the eyes is common and resolves within a week or two. Tenderness or numbness near the incision sites can linger for about a month.
The device isn’t turned on right away. About one month after the pulse generator is placed, you return to the clinic for initial programming. A specialist adjusts the stimulation settings, testing different combinations of contact points, voltage, and pulse width to find the combination that best controls your symptoms with the fewest side effects. This is rarely a one-visit process. Most patients need several programming sessions spaced about a month apart before reaching optimal settings. After that, adjustments drop to roughly every six months.
Living With the Device
The pulse generator runs on a battery implanted in your chest. Non-rechargeable models typically last three to five years before requiring a minor surgical replacement. Rechargeable models avoid frequent replacements but require regular charging sessions, usually by holding a charging pad against the chest for a set period each week. Neither option is clearly superior; it comes down to whether you’d rather deal with periodic replacement surgery or the routine of recharging.
Most people can return to normal daily activities within a few weeks of surgery, though contact sports and activities that risk head impact are generally discouraged. Certain medical procedures, particularly MRI scans, require special protocols because of the implanted hardware. Some newer DBS systems are designed to be MRI-compatible under specific conditions, which is worth discussing before surgery if you anticipate needing imaging in the future.
Who Benefits Most
DBS works best for people whose motor symptoms still respond to levodopa but who experience significant fluctuations, wearing-off periods, or dyskinesias that medication adjustments can’t adequately control. The ideal candidate has had Parkinson’s for at least four years, has a clear and confirmed diagnosis, and does not have significant dementia or untreated psychiatric illness. Age alone isn’t a disqualifier, but overall health needs to support a surgical procedure under anesthesia.
DBS is not a last resort. Some evidence suggests that earlier intervention, before motor complications become severe, may yield better quality-of-life outcomes. The decision involves weighing surgical risks (infection, bleeding, hardware complications) against the expected years of improved symptom control. For the right patient, the benefit is often transformative: more hours each day with functional movement, fewer pills, and a more predictable body.